A growing number of biotechnology inventions relate to peptides, oligonucleotides and other small molecules that could be used in therapeutic applications. Caroline Pallard explains the challenges of patenting such inventions.
A peptide can be used, for example, as a vaccine, while an oligonucleotide can be used to silence a given gene whose expression product is involved in the development of a disease. Normally, biotechnology patent applications disclose a high number of peptides or oligonucleotides. The applicant usually follows this strategy in order to reduce the filing costs by gathering several peptides/oligonucleotides in a single application.
However, this is not without risk, since at the time of filing the application, the applicant may not yet know which peptides or oligonucleotides will prove to be the most promising. This article gives an overview of some of the problems encountered in Europe by this type of patent application.
Lack of unity
Life Sciences Intellectual Property Review (LSIPR) tracks the increasing challenges for intellectual property specialists in the rapidly evolving world of life sciences. From gene patents to stem cell research, we provide the very best news and analysis.
To continue reading this article and to access 4,500+ articles, our digital magazines and special reports published for LSIPR subscribers only then you will need a subscription.
If you are already subscribed please login.
Official LSIPR subscribers include:
Allen & Overy
Arnold & Siedsma
Birch, Stewart, Kolasch & Birch LLP (BSKB)
Carpmaels & Ransford
Cooley
European Patent Office
Finnegan LLP
GH Research
Gowling WLG
George Washington Law School
HGF Limited
IQVIA
Kirkland & Ellis International LLP
Marks & Clerk
Mintz Levin
NiKang Therapeutics Inc.
Powell Gilbert LLP
Procopio, Cory, Hargreaves & Savitch LLP
Taylor Wessing
The United States Patent and Trademark Office (USPTO)
Valea AB
World Intellectual Property Office
For multi-user price options, or to check if your company has an existing subscription we can add you into for FREE, please contact Atif at achoudhury@newtonmedia.co.
If you have any technical issues please email tech support.
Patent protection, peptides, oligonucleotides, vaccines, inventive step